{"id":"NCT00863655","sponsor":"Novartis Pharmaceuticals","briefTitle":"Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole","officialTitle":"A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06-03","primaryCompletion":"2014-12-04","completion":"2014-12-04","firstPosted":"2009-03-18","resultsPosted":"2012-08-31","lastUpdate":"2017-05-02"},"enrollment":724,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Everolimus","otherNames":["RAD001"]},{"type":"DRUG","name":"Exemestane","otherNames":[]},{"type":"DRUG","name":"Everolimus Placebo","otherNames":[]}],"arms":[{"label":"Everolimus + Exemestane","type":"EXPERIMENTAL"},{"label":"Placebo + Exemestane","type":"ACTIVE_COMPARATOR"}],"summary":"There are no treatments specifically approved after recurrence or progression on a non steroidal aromatase inhibitors (NSAI). In light of the need for new treatment options for postmenopausal women after failure of prior NSAI therapy, the purpose of this Phase III study is to compare efficacy and safety of a treatment with exemestane + everolimus to exemestane + placebo in postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer refractory to NSAI.","primaryOutcome":{"measure":"Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments.","timeFrame":"date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months","effectByArm":[{"arm":"Everolimus + Exemestane","deltaMin":6.93,"sd":null},{"arm":"Placebo + Exemestane","deltaMin":2.83,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":200,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Czechia","Egypt","France","Germany","Hong Kong","Hungary","Italy","Japan","Netherlands","New Zealand","Norway","Poland","South Korea","Spain","Sweden","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["29522361","27532364","26503204","25231953","24615500","24158787","23962028","23404211","22149876"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":158,"n":482},"commonTop":["Stomatitis","Stomatitis","Fatigue","Fatigue","Nausea"]}}